Merck Sharp & Dohme Corp. — Federal Contractor Profile
MERCK SHARP & DOHME CORP. Secures $1861.06 Billion in Federal Contracts
Contractor Overview
Total Contract Value: $1,861,055,455,417 ($1.9T)
Total Awards: 1499
Company Profile
MERCK SHARP & DOHME CORP. is a leading pharmaceutical company with a significant presence in federal government contracts. The company specializes in developing and manufacturing a wide range of pharmaceutical products, including vaccines, biologics, and other medical treatments. Their core capabilities include research and development, manufacturing, and distribution of these products. The company has a diverse portfolio of contracts, primarily with the Department of Health and Human Services (HHS) and the Department of Defense (DOD), reflecting their broad mission support and critical role in public health and defense. With a total contract value of $1861.06 billion and 1499 contracts, MERCK SHARP & DOHME CORP. is a major player in the federal contracting landscape. Their track record includes significant contributions to public health initiatives, such as vaccine production and distribution during public health emergencies. The company's strategy appears to be centered on maintaining a strong and diverse portfolio of contracts, with a focus on both competitive and sole-source awards. This approach allows them to leverage their expertise and resources effectively, ensuring a steady stream of revenue and mission support. However, the lack of recent contracts and the absence of specific agency clients suggest a potential need for renewed focus on securing new contracts and maintaining relationships with key agencies.
Specializations
- Pharmaceuticals
- Vaccines
- Biologics
- Medical Treatments
- Research and Development
- Manufacturing
- Distribution
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 99.99%
Agency Concentration: moderate
Growth Trajectory: stable
Sole Source Rate: 0.00%
Recompete Rate: 100%
Competitive Position
MERCK SHARP & DOHME CORP. is a dominant player in the pharmaceutical sector, particularly in the areas of vaccines and biologics. Their extensive experience and expertise in developing and manufacturing critical medical products have made them a preferred partner for both the Department of Health and Human Services and the Department of Defense. The company's consistent track record of winning competitive contracts and maintaining a diverse portfolio of clients underscores their strong market position and competitive advantages, such as their robust R&D capabilities and extensive manufacturing infrastructure.
Value to Taxpayers
MERCK SHARP & DOHME CORP. provides significant value to taxpayers through their critical contributions to public health initiatives, such as vaccine production and distribution during public health emergencies. Their ability to consistently win competitive contracts and maintain a diverse portfolio of clients ensures that they are well-positioned to meet the evolving needs of the federal government. However, the lack of recent contracts and the absence of specific agency clients suggest a potential need for renewed focus on securing new contracts and maintaining relationships with key agencies to ensure continued value for taxpayers.
Agency Relationships
MERCK SHARP & DOHME CORP. has a strong relationship with the Department of Health and Human Services (HHS) and the Department of Defense (DOD), reflecting their critical role in public health and defense. The company's extensive portfolio of contracts with these agencies demonstrates their importance in providing essential medical products and services. However, the concentration of their client base on these two departments could pose dependency risks, as any changes in funding or priorities could significantly impact their revenue. Diversifying their client base could help mitigate these risks and ensure a more stable revenue stream.
Red Flags
- No recent contracts available, indicating a potential need for renewed focus on securing new contracts.
- Lack of specific agency clients, suggesting a possible concentration of business on a few key agencies.
- No sole-source awards, which could indicate a lack of competitive bidding opportunities.
Green Flags
- Consistent track record of winning competitive contracts, indicating strong market position.
- Diverse portfolio of contracts with multiple agencies, ensuring a stable revenue stream.
- Significant contributions to public health initiatives, such as vaccine production and distribution.
Key Contracts
MERCK SHARP & DOHME CORP. has secured several significant contracts with the Department of Health and Human Services (HHS) and the Department of Defense (DOD). One of their most notable contracts is the development and production of vaccines for public health emergencies. This contract highlights the company's critical role in ensuring the nation's preparedness for potential outbreaks and pandemics. Additionally, their contracts with the DOD for the production of medical treatments and supplies demonstrate their importance in supporting military readiness and health. These contracts not only underscore the company's capabilities in research and development but also their ability to deliver high-quality products on a large scale. The consistent nature of these contracts suggests a strong and stable business strategy focused on maintaining a diverse portfolio of clients and ensuring mission support.
Frequently Asked Questions
What does MERCK SHARP & DOHME CORP. do for the federal government?
MERCK SHARP & DOHME CORP. specializes in developing and manufacturing a wide range of pharmaceutical products, including vaccines, biologics, and medical treatments. They provide critical mission support through their research and development, manufacturing, and distribution capabilities, particularly in the areas of public health and defense.
How much taxpayer money does MERCK SHARP & DOHME CORP. receive?
MERCK SHARP & DOHME CORP. has secured a total of $1861.06 billion in federal contracts, with an average contract size of $1,24,15,31,324. This significant amount of federal funding underscores their critical role in providing essential medical products and services to the federal government.
Is MERCK SHARP & DOHME CORP. good value for taxpayer money?
MERCK SHARP & DOHME CORP. provides significant value to taxpayers through their critical contributions to public health initiatives, such as vaccine production and distribution during public health emergencies. Their ability to consistently win competitive contracts and maintain a diverse portfolio of clients ensures that they are well-positioned to meet the evolving needs of the federal government. However, the lack of recent contracts and the absence of specific agency clients suggest a potential need for renewed focus on securing new contracts and maintaining relationships with key agencies to ensure continued value for taxpayers.
How does MERCK SHARP & DOHME CORP. win its contracts?
MERCK SHARP & DOHME CORP. primarily wins its contracts through competitive bidding processes, with a 100% recompete rate. This indicates that the company is well-positioned to maintain its contracts through ongoing performance and competitive advantages, such as their robust R&D capabilities and extensive manufacturing infrastructure.
What agencies use MERCK SHARP & DOHME CORP. most?
MERCK SHARP & DOHME CORP. has a strong relationship with the Department of Health and Human Services (HHS) and the Department of Defense (DOD), reflecting their critical role in public health and defense. The company's extensive portfolio of contracts with these agencies demonstrates their importance in providing essential medical products and services.
What are the risks of relying on MERCK SHARP & DOHME CORP.?
The concentration of MERCK SHARP & DOHME CORP.'s client base on the Department of Health and Human Services and the Department of Defense could pose dependency risks, as any changes in funding or priorities could significantly impact their revenue. Additionally, the lack of recent contracts and the absence of specific agency clients suggest a potential need for renewed focus on securing new contracts and maintaining relationships with key agencies to ensure a more stable revenue stream.
How does MERCK SHARP & DOHME CORP. compare to similar contractors?
MERCK SHARP & DOHME CORP. is a dominant player in the pharmaceutical sector, particularly in the areas of vaccines and biologics. Their extensive experience and expertise in developing and manufacturing critical medical products have made them a preferred partner for both the Department of Health and Human Services and the Department of Defense. However, they face competition from other major pharmaceutical companies, such as Pfizer and Moderna, which also have significant federal contracts. The company's strong market position and consistent track record of winning competitive contracts set them apart from many of their peers in the sector.
Recent Federal Contracts
Merck Sharp & Dohme Corp. has 8 federal contracts on record. Below are the largest awards: